Key result
Evolocumab initiation linked to ~53% median LDL-C reduction in routine clinical practice.
Why the study?
LDL-C is a key modifiable cardiovascular risk factor and data on evolocumab effectiveness and LDL-C control in high and very high-risk patients in German clinical practice were needed.
Does evolocumab improve LDL-C control and goal attainment in high and very high cardiovascular risk patients in routine clinical practice?
Cohort (n=380)
Yes
Does evolocumab improve LDL-C control and goal attainment in high and very high cardiovascular risk patients in routine clinical practice?
In a real-world German cohort of high and very high-risk patients, evolocumab achieved rapid and sustained median LDL-C reductions of 53%, with higher guideline goal attainment observed when used in combination with background lipid-lowering therapies.
Answers are grounded in this paper and cite their sources.
Evolocumab was associated with sustained LDL-C reduction and high persistence in high-risk patients; extends real-world evidence but leaves open CV outcome confirmation.
INTRODUCTION: Low-density lipoprotein cholesterol (LDL-C) is among the most important modifiable risk factors for cardiovascular disease. In very high-risk patients, the European Society of Cardiology/European Atherosclerosis Society guidelines recommend attaining LDL-C < 55 mg/dL. In the German cohort of the observational HEYMANS study, we aimed to describe the clinical characteristics and LDL-C control among patients initiating evolocumab. METHODS: Data was collected between 09/2016 and 05/2021 for ≤ 6 months before (retrospectively) and ≤ 30 months after evolocumab initiation (prospectively). Patient characteristics, lipid-lowering therapy (LLT), lipid values, evolocumab use, and safety were collected. RESULTS: Of 380 enrolled patients, 93% received evolocumab in secondary prevention and 69% had a history of statin intolerance. At study baseline, 49% did not receive any statins and LDL-C was very high (145 mg/dL). Use of evolocumab decreased LDL-C by a median of 53% within 3 months and remained stable thereafter, despite mainly unchanged background LLT. Overall, 59% attained an LDL-C level < 55 mg/dL (69% with, 49% without LLT). Persistence to evolocumab was 90.6% in months 1-12 and 93.5% in months 13-30. Adverse drug reactions were reported in 8% of patients. CONCLUSION: Data from the German HEYMANS cohort corroborate previous reports on evolocumab effectiveness and safety in clinical practice. Evolocumab initiation was associated with a rapid and sustained LDL-C reduction. Persistence with evolocumab was high. Our finding that patients receiving an evolocumab/LLT combination are more likely to attain the LDL-C goal than those receiving evolocumab alone corroborates previous data showing the importance of using highly intensive therapy. Graphical abstract available for this article. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT02770131 (registration date 27 April 2016).
No takes yet. Share an insight, caveat, or question.
Lehrke et al. (2024) conducted a cohort in Dyslipidemia in high and very high cardiovascular risk patients (n=380). Evolocumab was evaluated on Median percentage reduction in LDL-C from baseline within 3 months. Evolocumab initiation in routine clinical practice was associated with a rapid and sustained median LDL-C reduction of 53% within 3 months, with 59% of patients attaining an LDL-C level < /dL.
Synapse has enriched 10 related papers. Consider them for comparative context: